在姐妹研究队列中,抑郁症,抗抑郁药的使用和乳腺癌发病率
Mary V Díaz-Santana1, Jihye Park2, Molly Rogers3
1Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Dr., Durham, NC, 27709, USA. mary.diazsantana@nih.gov.
Breast cancer research : BCR
|May 15, 2025
概括
抑郁病史没有影响乳腺癌风险. 然而,抗抑郁药的使用,特别是SSRI,与风险降低有关,特别是在BMI较低的女性中.
科学领域:
- 在瘤学瘤学.
- 精神病学是一个精神病学.
- 流行病学 流行病学
背景情况:
- 关于抑郁症对乳腺癌风险的影响,有不同的发现.
- 评估被诊断出抑郁症与乳腺癌风险之间的关联至关重要.
研究的目的:
- 调查诊断抑郁症史与乳腺癌风险之间的关系.
- 检查抗抑郁药使用与乳腺癌风险之间的关联.
- 探索抗抑郁药类和BMI水平之间降低风险的潜在差异.
主要方法:
- 对45746名姐妹研究队列 (2003-2009) 的女性数据的分析.
- 使用Cox比例危险回归来估计乳腺癌的危险比率 (HR).
- 对抗抑郁药使用的时间依赖性分析.
主要成果:
- 在被诊断为抑郁症的病史和乳腺癌风险 (HR=0.98) 之间没有发现显著的关联.
- 抗抑郁药的使用与乳腺癌风险降低有关 (HR=0.92).
- 选择性血清素再吸收抑制剂 (SSRI) 显示出一种相反的关联 (HR=0.90),在BMI<25 (HR=0.72) 的女性中效果更强.
结论:
- 没有发现抑郁症本身与乳腺癌风险有关.
- 在使用抗抑郁药物,特别是SSRI时,观察到潜在的风险降低.
- 较低BMI个体中较强的关联可能表明剂量依赖的效果,需要进一步调查.
相关概念视频
Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
Depression: Overview
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...


